Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aclaris Therapeutics ( (ACRS) ) has issued an announcement.
On March 10, 2026, Aclaris Therapeutics, Inc. raised $20 million in gross proceeds through the sale of 5.7 million shares of its common stock under an amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. The shares were purchased by prominent life sciences investors Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP, underscoring continued institutional support and providing additional capital to fund the company’s operations and strategic initiatives.
The transaction, executed pursuant to an at-the-market style equity arrangement updated in February 2025, diversified Aclaris’s shareholder base with sector-focused funds and reinforced its access to public equity markets. This equity raise, while dilutive to existing shareholders, strengthened the company’s balance sheet and may enhance its flexibility in advancing its development programs and pursuing its business objectives within the competitive biopharmaceutical landscape.
The most recent analyst rating on (ACRS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
The score is held down primarily by weak financial performance—shrinking revenue, very large losses, and sustained cash burn—despite low leverage. Offsetting factors include a generally positive price trend and favorable corporate developments (liquidity raise and encouraging early-stage pipeline progress), while valuation is difficult to assess given negative earnings.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, primarily in dermatology and immuno-inflammatory disorders. The company targets unmet medical needs in these therapeutic areas, positioning itself within the life sciences sector and attracting specialized healthcare and life science investors.
Average Trading Volume: 2,260,234
Technical Sentiment Signal: Buy
Current Market Cap: $442.6M
See more insights into ACRS stock on TipRanks’ Stock Analysis page.